Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 4Unknown 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × tepotinib × Clear all
NCT06031688 2026-05-05

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Recruiting
56 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Samsung Medical Center

Phase 2 Recruiting
47 enrolled
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT05159245 2024-07-15

FINPROVE

Helsinki University Central Hospital

Phase 2 Recruiting
250 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡